| 1 |
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Jean‐Charles Soria et al. · New England Journal of Medicine
Open access |
18 Nov 2017 |
5,475 |
| 2 |
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al. · New England Journal of Medicine
Open access |
4 Jun 2018 |
3,816 |
| 3 |
Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine
Shinichi Sakuramoto, Mitsuru Sasako, Toshiharu Yamaguchi et al. · New England Journal of Medicine
Open access |
31 Oct 2007 |
2,547 |
| 4 |
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al. · New England Journal of Medicine
Open access |
11 Dec 2019 |
2,026 |
| 5 |
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Norikazu Masuda et al. · New England Journal of Medicine
Open access |
31 May 2017 |
1,947 |
| 6 |
A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)
Nobutoshi Ando, Hoichi Kato, Hiroyasu Igaki et al. · Annals of Surgical Oncology
Open access |
30 Aug 2011 |
1,459 |
| 7 |
D2 Lymphadenectomy Alone or with Para-aortic Nodal Dissection for Gastric Cancer
Mitsuru Sasako, Takeshi Sano, Seiichiro Yamamoto et al. · New England Journal of Medicine
Open access |
30 Jul 2008 |
1,029 |
| 8 |
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Martin Reck et al. · The Lancet Respiratory Medicine
|
26 Mar 2019 |
954 |
| 9 |
Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
Toyoaki Hida et al. · The Lancet
|
11 May 2017 |
927 |
| 10 |
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Thanyanan Reungwetwattana, Kazuhiko Nakagawa, Byoung Chul Cho et al. · Journal of Clinical Oncology
Open access |
28 Aug 2018 |
804 |
| 11 |
Gastric Cancer Surgery: Morbidity and Mortality Results From a Prospective Randomized Controlled Trial Comparing D2 and Extended Para-Aortic Lymphadenectomy—Japan Clinical Oncology Group Study 9501
Takeshi Sano, Mitsuru Sasako, Seiichiro Yamamoto et al. · Journal of Clinical Oncology
|
17 Jun 2004 |
679 |
| 12 |
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
Robert M. Jotte, Federico Cappuzzo, Ihor O. Vynnychenko et al. · Journal of Thoracic Oncology
Open access |
14 Apr 2020 |
618 |
| 13 |
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
Narikazu Boku, Seiichiro Yamamoto, Haruhiko Fukuda et al. · The Lancet Oncology
|
9 Oct 2009 |
594 |
| 14 |
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
Takashi Seto, Katsuyuki Kiura, Makoto Nishio et al. · The Lancet Oncology
|
29 Apr 2013 |
579 |
| 15 |
Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial
Shuichi Hironaka, Shinya Ueda, Hirofumi Yasui et al. · Journal of Clinical Oncology
|
4 Nov 2013 |
570 |
| 16 |
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
Mark A. Socinski, Makoto Nishio, Robert M. Jotte et al. · Journal of Thoracic Oncology
Open access |
24 Jul 2021 |
546 |
| 17 |
Zoledronic Acid Significantly Reduces Skeletal Complications Compared With Placebo in Japanese Women With Bone Metastases From Breast Cancer: A Randomized, Placebo-Controlled Trial
Norio Kohno, Kenjiro Aogi, Hironobu Minami et al. · Journal of Clinical Oncology
|
Mar 2005 |
546 |
| 18 |
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer
Yasuhide Yamada et al. · Annals of Oncology
Open access |
15 Oct 2014 |
546 |
| 19 |
Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial
Mitsue Saito, Kenjiro Aogi, Ikuo Sekine et al. · The Lancet Oncology
|
9 Jan 2009 |
437 |
| 20 |
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
Salvatore Siena et al. · The Lancet Oncology
|
4 May 2021 |
426 |
| 21 |
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
Yoshiaki Nakamura et al. · Nature Medicine
|
5 Oct 2020 |
380 |
| 22 |
Nationwide Survey on Complementary and Alternative Medicine in Cancer Patients in Japan
Ichinosuke Hyodo, Noriko Amano, Kenji Eguchi et al. · Journal of Clinical Oncology
Open access |
23 Feb 2005 |
347 |
| 23 |
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial
Chigusa Morizane et al. · Annals of Oncology
Open access |
26 Sep 2019 |
338 |
| 24 |
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial
Takayuki Yoshino, Nobuyuki Mizunuma, Kentaro Yamazaki et al. · The Lancet Oncology
|
27 Aug 2012 |
326 |
| 25 |
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain
Naoyuki Nogami et al. · Journal of Thoracic Oncology
Open access |
7 Oct 2021 |
313 |
| 26 |
Differences between right‐ and left‐sided colon cancer in patient characteristics, cancer morphology and histology
Toru Nawa, Jun Kato, Hirofumi Kawamoto et al. · Journal of Gastroenterology and Hepatology
|
27 May 2007 |
299 |
| 27 |
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
Kiyotaka Yoh, Takashi Seto, Miyako Satouchi et al. · The Lancet Respiratory Medicine
|
5 Nov 2016 |
298 |
| 28 |
Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV ‐8‐negative multicentric Castleman disease
Noriko Iwaki et al. · American Journal of Hematology
Open access |
17 Nov 2015 |
293 |
| 29 |
A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: The Japan clinical oncology group study
Nobutoshi Ando, Toshifumi Iizuka, Teruo Kakegawa et al. · Journal of Thoracic and Cardiovascular Surgery
Open access |
Aug 1997 |
286 |
| 30 |
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)
K. Yamazaki et al. · Annals of Oncology
Open access |
14 May 2016 |
285 |
| 31 |
Natural History of Pulmonary Subsolid Nodules: A Prospective Multicenter Study
Ryutaro Kakinuma, Masayuki Noguchi, Kazuto Ashizawa et al. · Journal of Thoracic Oncology
Open access |
16 Apr 2016 |
278 |
| 32 |
Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial
Ken Kato et al. · The Lancet
|
12 Jun 2024 |
276 |
| 33 |
Chemotherapy for hepatocellular carcinoma: current status and future perspectives
Masafumi Ikeda, Chigusa Morizane, Makoto Ueno et al. · Japanese Journal of Clinical Oncology
Open access |
24 Nov 2017 |
276 |
| 34 |
Focal Ground-Glass Opacity Detected by Low-Dose Helical CT
Masao Nakata, Hideyuki Saeki, Ichiro Takata et al. · CHEST Journal
|
May 2002 |
276 |
| 35 |
A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer
Kei Muro, Tsuyoshi Hamaguchi, Atsushi Ohtsu et al. · Annals of Oncology
Open access |
19 May 2004 |
269 |
| 36 |
Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602
Takashi Onda, Toyomi Satoh, Toshiaki Saito et al. · European Journal of Cancer
|
18 Jun 2016 |
259 |
| 37 |
Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study
David Scott Miller, Virginia L. Filiaci, Gini F. Fleming et al. · Gynecologic Oncology
|
17 May 2012 |
256 |
| 38 |
Anamorelin (ONO‐7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04)
Nobuyuki Katakami, Junji Uchino, Takuma Yokoyama et al. · Cancer
Open access |
4 Dec 2017 |
247 |
| 39 |
Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome
Tsunehisa Kaku, Hiroyuki Yoshikawa, Hitoshi Tsuda et al. · Cancer Letters
|
Jun 2001 |
246 |
| 40 |
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
Helena Alexandra Yu et al. · Journal of Clinical Oncology
Open access |
10 Sep 2023 |
245 |
| 41 |
Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial
Yoshiaki Nakamura et al. · Nature Medicine
Open access |
Nov 2021 |
245 |
| 42 |
Computer-aided diagnosis for pulmonary nodules based on helical CT images
Keizo Kanazawa, Yoshiki Kawata, Noboru Niki et al. · Computerized Medical Imaging and Graphics
|
Mar 1998 |
241 |
| 43 |
Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system
Tomohiro Yamaguchi, Nozomu Machida, Chigusa Morizane et al. · Cancer Science
Open access |
28 Jun 2014 |
239 |
| 44 |
Hepatectomy Followed by mFOLFOX6 Versus Hepatectomy Alone for Liver-Only Metastatic Colorectal Cancer (JCOG0603): A Phase II or III Randomized Controlled Trial
Yukihide Kanemitsu et al. · Journal of Clinical Oncology
|
14 Sep 2021 |
228 |
| 45 |
Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial
Takashi Onda, Toyomi Satoh, Gakuto Ogawa et al. · European Journal of Cancer
|
13 Mar 2020 |
227 |
| 46 |
Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial
Kohei Shitara, Atsuo Takashima, Kazumasa Fujitani et al. · The Lancet. Gastroenterology & hepatology
|
18 Jan 2017 |
227 |
| 47 |
Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non–Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR
Masaru Watanabe, Tomoya Kawaguchi, Shun‐ichi Isa et al. · Clinical Cancer Research
|
16 Apr 2015 |
227 |
| 48 |
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)
Kei Muro, Narikazu Boku, Yasuhiro Shimada et al. · The Lancet Oncology
|
13 Aug 2010 |
221 |
| 49 |
Carotenoids in Cancer Chemoprevention
Hoyoku Nishino, Michiaki Murakoshi, Tsunehiro Ii et al. · Cancer and Metastasis Reviews
|
Dec 2002 |
217 |
| 50 |
Efficacy of Endoscopic Resection and Selective Chemoradiotherapy for Stage I Esophageal Squamous Cell Carcinoma
Keiko Minashi et al. · Gastroenterology
Open access |
20 Apr 2019 |
216 |